

## Certificate of Analysis

### EphA2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-560, 14-560-K, 14-560M

Parent Lot # 28594U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant human EphA2 residues 596–900, expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>/NTA-agarose. Purity 96% by SDS-PAGE and Coomassie blue staining. MW = 38kDa.

**Specific Activity (Parent lot# 28594U):** 268U/mg, where one unit of EphA2, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

**Formulation:** 1.18mg/ml of enzyme in 50mM HEPES pH7.0, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**


### Quality Control Testing

**Kinase Assay:** 11.8–59ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed identity as EphA2 with the translated sequence listed on page three.

**SDS-PAGE and Coomassie Stain:** Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of EphA2, active.



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock and add 2.5µl of stock per assay point.
3. **EphA2, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 11.8–59ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells
2. Add 2.5µl of **poly(Glu, Tyr) (4:1)**.
3. Add **2.5µl (11.8–59ng) EphA2, active**.
4. Add 5µl of dH<sub>2</sub>O.
5. Add 10µl of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

# Certificate of Analysis

## EphA2 Sequence Information

|                                |                                                                     |
|--------------------------------|---------------------------------------------------------------------|
| <b><u>Protein</u></b>          | human EphA2                                                         |
| <b><u>Tags</u></b>             | N-terminal 6His                                                     |
| <b><u>Native sequence</u></b>  | D29 of the recombinant protein is equivalent to D596 of human EphA2 |
| <b><u>Accession number</u></b> | GenBank NM_00431                                                    |

### Recombinant EphA2 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMGSDP NQAVLKFTTE IHPSCVTRQK VIGAGEFGEV
61 YKGLMKTSSG KKEVPVAIKT LKAGYTEKQR VDFLGEAGIM GQFSHHNIIR LEGVISKYKP
121 MMIITEYMEN GALDKFLREK DGEFSVLQLV GMLRGIAAGM KYLANMNYVH RDLAARNILV
181 NSNLVCKVSD FGLSRVLEDD PEATYTTSSG KIPIRWTAPE AISYRKFTSA SDVWSFGIVM
241 WEVMTYGERP YWELSNHEVM KAINDGFRLP TPMDCPSAIY QLMMQCWQQE RARRPKFADI
301 VSILDKLIRA PDSLKTLADF DPRVSIRLPS TSG

```

### Recombinant EphA2 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tatttttcagg gcgccatggg atctgacccc aaccaggctg tgttgaagtt cactaccgag
121 atccatccat cctgtgtcac tcggcagaag gtgatcggag caggagagtt tggggagggtg
181 tacaagggca tgctgaagac atcctcgggg aagaaggagg tgccggtggc catcaagacg
241 ctgaaagccg gctacacaga gaagcagcga gtggacttcc tcggcgaggc cggcatcatg
301 ggccagttca gccaccacaa catcatccgc ctagagggcg tcatctccaa atacaagccc
361 atgatgatca tcaactgagta catggagaat ggggcccttg acaagtctct tcgggagaag
421 gatggcgagt tcagcgtgct gcagctgggt ggcacgtctg ggggcatcgc agctggcatg
481 aagtacctgg ccaacatgaa ctatgtgcac cgtgacctgg ctgcccgcaa catcctcgtc
541 aacagcaacc tgggtctgca ggtgtctgac tttggcctgt cccgctgtgt ggaggacgac
601 cccgaggcca cctacaccac cagtggcggc aagatcccca tccgctggac cgccccggag
661 gccatttcct accggaagtt cacctctgcc agcgacgtgt ggagcttttg cattgtcatg
721 tgggagggtg tgacctatgg cgagcggccc tactgggagt tgtccaacca cgaggtgatg
781 aaagccatca atgatggctt ccggctcccc acacccatgg actgcccctc cgccatctac
841 cagctcatga tgcagtgtg gcagcaggag cgtgcccgcc gccccaagtt cgctgacatc
901 gtcagcatcc tggacaagct cattcgtgcc cctgactccc tcaagacctt ggetgacttt
961 gacccccgcg tgtctatccg gctccccagc acgagcggct ag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.